A medical team has recently used tissue cells from a patient's nose to reconnect the nerve endings in his severed spinal column so that function was restored enabling the patient to have partial use of his legs.
This ground breaking medical treatment will cause many spinal injury victims to question whether they may be able to benefit from such treatment and gain greater mobility.
This news will lead lawyers to ask for the treatment to be funded for their clients. On the other hand, compensators may be understandably cautious of supporting cutting edge treatment still in the early stages of development. They will need to balance the risk of paying significant costs for uncertain outcomes against the possibility that increased mobility for a claimant may vastly reduce the value of the future care claim and give the claimant a significantly improved chance of enjoying greater independence and opportunity on the labour market.